Renal pericytes have been neglected for many years, but recently they have become an intensively studied cell population in renal biology and pathophysiology. Pericytes are stromal cells that support vasculature, and a subset of pericytes are mesenchymal stem cells. In kidney, pericytes have been reported to play critical roles in angiogenesis, regulation of renal medullary and cortical blood flow, and serve as progenitors of interstitial myofibroblasts in renal fibrogenesis. They interact with endothelial cells through distinct signaling pathways and their activation and detachment from capillaries after acute or chronic kidney injury may be critical for driving chronic kidney disease progression. By contrast, during kidney homeostasis it is likely that pericytes serve as a local stem cell population that replenishes differentiated interstitial and vascular cells lost during aging. This review describes both the regenerative properties of pericytes as well as involvement in pathophysiologic conditions such as fibrogenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163198 | PMC |
| http://dx.doi.org/10.1016/j.semnephrol.2014.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.
Biomaterials
May 2025
Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology, Hypertension), RWTH Aachen University Medical Faculty, Aachen, Germany; Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address:
Chronic kidney disease (CKD) affects more than 10% of the global population. As kidney function negatively correlates with the presence of interstitial fibrosis, the development of new anti-fibrotic therapies holds promise to stabilize functional decline in CKD patients. The goal of the study was to generate a scalable bioprinted 3-dimensional kidney tubulo-interstitial disease model of kidney fibrosis.
View Article and Find Full Text PDFRegulation of the blood-brain barrier function by peripheral cues in health and disease.
Metab Brain Dis
December 2024
Institute of Neurology (Edinger Institute), University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
The blood-brain barrier (BBB) is formed by microvascular endothelial cells which are ensembled with pericytes, astrocytes, microglia and neurons in the neurovascular unit (NVU) that is crucial for neuronal function. Given that the NVU and the BBB are highly dynamic and regulated structures, their integrity is continuously challenged by intrinsic and extrinsic factors. Herein, factors from peripheral organs such as gonadal and adrenal hormones may influence vascular function also in CNS endothelial cells in a sex- and age-dependent manner.
View Article and Find Full Text PDFBioinformatic characterization of ENPEP, the gene encoding a potential cofactor for SARS-CoV-2 infection.
PLoS One
December 2024
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Research on SARS-CoV-2, the viral pathogen that causes COVID-19, has identified angiotensin converting enzyme 2 (ACE2) as the primary viral receptor. Several genes that encode viral cofactors, such as TMPRSS2, NRP1, CTSL, and possibly KIM1, have since been discovered. Glutamyl aminopeptidase (APA), encoded by the gene ENPEP, is another cofactor candidate due to similarities in its biological role and high correlation with ACE2 and other human coronavirus receptors, such as aminopeptidase N (APN) and dipeptidyl peptidase 4 (DPP4).
View Article and Find Full Text PDFEmpagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
JAMA Ophthalmol
January 2025
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Empagliflozin may reduce the risk of diabetic retinopathy (DR) by preventing the loss of retinal pericytes, but its effectiveness compared to DPP4 inhibitors in patients with type 2 diabetes (T2D) is not well established.
- A study was conducted using U.S. insurance claims data from 2014 to 2019, focusing on adults with T2D who were newly prescribed either empagliflozin or a DPP4 inhibitor, and looking at the incidence of nonproliferative DR and its progression.
- Results showed that among matched patient pairs, empagliflozin's impact on the rates of incident DR and progression was analyzed, with significant data collected over an average
FUT8 upregulates CD36 and its core fucosylation to accelerate pericyte-myofibroblast transition through the mitochondrial-dependent apoptosis pathway during AKI-CKD.
Mol Med
November 2024
Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, 116011, PR China.
Background: Activation of pericytes leads to renal interstitial fibrosis, but the regulatory mechanism of pericytes in the progression from AKI to CKD remains poorly understood. CD36 activation plays a role in the progression of CKD. However, the significance of CD36 during AKI-CKD, especially in pericyte, remains to be fully defined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!